Gabriele Weitz-Schmidt, PhD, is the Chief Scientific Officer of AlloCyte, providing pharmacology and project management expertise. Gabriele is a pharmacist and biochemist who graduated at the University of Bonn, Germany, and received her venia docendi in pharmacy from the University of Basel. After post-doctoral research at the National Institutes of Health, Bethesda, she joined the Preclinical Research Department of Sandoz/Novartis, Basel, where she led global interdisciplinary projects in the areas of cardiovascular disease, transplant rejection and autoimmunity. Following a sabbatical in the laboratory of Timothy Springer, Gabriele decided to join the founding team of AlloCyte. Gabriele has published more than 50 peer-reviewed papers in the field of drug discovery in high-ranking journals including Nature Medicine, Immunity and the Journal of Biological Chemistry. The discoveries of her group significantly contribute to the understanding of integrin pharmacology, as highlighted by editorials and review articles in major journals. Gabriele currently serves as the President of the Swiss Society of Experimental Pharmacology (SSEP).



Albrecht-Georg Schmidt, MD, is the Chief Executive Officer of AlloCyte. Albrecht is a graduate from the University of Hamburg, Germany, and a board-certified internist from Medizinische Hochschule Hannover, Germany. Upon post-doctoral research at NIH, Bethesda, he joined Clinical Research and Development at Sandoz/Novartis in Basel where he led the clinical development of major immunomodulatory products of worldwide reach, including Neoral™ in rheumatoid arthritis and psoriasis and Simulect™ (basiliximab) in organ transplantation. As a global Section Head at Novartis, he responsibly oversaw the clinical development portfolios in the areas of immunology, transplantation, respiratory diseases, tropical medicine and dermatology. Albrecht led clinical development in immunology and infectious diseases at Actelion, Switzerland, before deciding to join the founding team of AlloCyte. Albrecht co-authored papers in ranking journals including Science, The Lancet and the Journal of Biological Chemistry and articles in specialty journals in clinical pharmacology, transplantation, rheumatology and dermatology.



Gisbert Schneider, PhD, brings leading expertise in computer-assisted drug design (CADD) to AlloCyte. Gisbert studied biochemistry and computer science and received his doctoral degree at the Free University of Berlin, Germany. After post-doctoral research at Benjamin-Franklin Clinic in Berlin, Stockholm University, M.I.T. Cambridge, and Max-Planck Institute for Biophysics in Frankfurt, he joined F.Hoffmann-La Roche Pharmaceuticals in Basel, Switzerland, where he headed the cheminformatics group. He received his habilitation and venia legendi in biochemistry and bioinformatics from the University of Freiburg, Germany. From 2002-2009 he held the position of a Full Professor of Chem- and Bioinformatics (Beilstein Endowed Chair) at Goethe-University Frankfurt, Germany; now Distinguished Adjunct Professor at Goethe-University. In 2010 he joined ETH Zürich, Switzerland, as a Full Professor of Computer-Assisted Drug Design. Gisbert pioneered the application of machine learning methods for de novo drug design. His leading position in the field is mirrored by top-ranking publications, including several authoritative reviews in Nature Reviews Drug Discovery.


Timothy Springer, PhD, is a world-leading researcher at Harvard Medical School in Boston. Tim discovered integrins and characterized their mechanisms of activation in molecular detail. His research laid the groundwork for integrins as therapeutic targets. With more than 500 publications of high impact Tim is one of the most-cited researchers worldwide. Tim has been the founder of LeukoSite, acquired by Millennium Pharmaceuticals subsequently. Three FDA approved drugs, Campath™ (alemtuzumab) for chronic lymphocytic leukemia, Velcade™ (bortezomib) for multiple myeloma and Entyvio(vedolizumab) for Crohn's disease and ulcerative colitis, originate from LeukoSite’s pipeline. In addition, Tim worked with Biogen to develop Amevive™ (alefacept) which was approved by the FDA in 2003. Tim is a founding member, investor and SAB member of Selecta Biosciences, working on nanoparticle-based targeted synthetic vaccines, and an investor, board member, and SAB member of Moderna Therapeutics, working on protein delivery in vivo using modified RNA.



Daniel Gygax, PhD, provides the company with unique access to innovative technology and methodology infrastructure at Fachhochschule Nordwestschweiz (FHNW), Basel, enabling Allocyte’s efficient assay methodologies. Daniel studied biology and biochemistry and received his PhD at the University of Basel, Switzerland. After post-doctoral research at Harvard University in Cambridge he joined Pre-Clinical Research at Ciba-Geigy/Novartis in Basel. As the Head of Immunoanalytics and Pharmacokinetics at Novartis he supported major pre-clinical and clinical drug development projects. As Professor for Bioanalytics and Biotechnology at FHNW, his research focuses on innovative biotechnological and bioanalytical methodologies for drug developmental, diagnostic and therapeutic applications. Daniel’s work has been recognised by several awards. He takes a prominent role in promoting applied pharmacological research in Switzerland and internationally. He currently serves as the President of Biotechnet Switzerland and is a senior member of the Swiss Academy of Engineering Sciences (SATW), the Swiss Chemical Society, and the Swiss Center for Technology Assessment (TA Swiss).




Elisabeth Flury brings with her more than 25 years of international professional experience in both the areas of Finance & Administration and Human Resources. Most recently, she has been responsible for Human Resources at Speedel, Basel, where she also supported the Finance organization during the company’s initial public offering. Prior to this affiliation, Elisabeth worked in international assignments for Fisher Scientific, Covance, and MDL, where she established efficient accounting teams throughout Europe, and implemented corporate guidelines, policies, and reporting infrastructures for US-headquartered international companies.